ADMA Biologics, Inc. – NASDAQ:ADMA
Founder-led company
ADMA Biologics stock price today
$17.48
+0.03
+0.17%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 15 minutes
ADMA Biologics stock price monthly change
+36.54%
month
ADMA Biologics stock price quarterly change
+36.54%
quarter
ADMA Biologics stock price yearly change
+288.64%
year
ADMA Biologics key metrics
Market Cap | 4.12B |
Enterprise value | 707.05M |
P/E | -9.23 |
EV/Sales | 3.25 |
EV/EBITDA | -10.30 |
Price/Sales | 2.94 |
Price/Book | 4.20 |
PEG ratio | -0.26 |
EPS | -0.01 |
Revenue | 283.17M |
EBITDA | 53.35M |
Income | -3.64M |
Revenue Q/Q | 43.85% |
Revenue Y/Y | 55.68% |
Profit margin | -48.22% |
Oper. margin | -29.18% |
Gross margin | 21.51% |
EBIT margin | -29.18% |
EBITDA margin | 18.84% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeADMA Biologics stock price history
ADMA Biologics stock forecast
ADMA Biologics financial statements
Average Price Target
$18
Potential upside: 2.97%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 60.12M | -6.37M | -10.6% |
|---|---|---|---|
| Sep 2023 | 67.27M | 2.56M | 3.81% |
| Dec 2023 | 73.90M | -17.64M | -23.88% |
| Mar 2024 | 81.87M | 17.80M | 21.75% |
| Jun 2023 | 343027042 | 196.26M | 57.22% |
|---|---|---|---|
| Sep 2023 | 348996565 | 197.55M | 56.61% |
| Dec 2023 | 329182000 | 193.97M | 58.93% |
| Mar 2024 | 350875000 | 197.16M | 56.19% |
| Jun 2023 | -6.05M | -872.63K | 240.11K |
|---|---|---|---|
| Sep 2023 | 11.98M | -756.55K | 415.35K |
| Dec 2023 | 17.59M | -1.40M | -38.99M |
| Mar 2024 | -2.21M | -2.36M | -1.44M |
ADMA Biologics alternative data
| Aug 2023 | 617 |
|---|---|
| Sep 2023 | 617 |
| Oct 2023 | 617 |
| Nov 2023 | 617 |
| Dec 2023 | 617 |
| Jan 2024 | 617 |
| Feb 2024 | 617 |
| Mar 2024 | 624 |
| Apr 2024 | 624 |
| May 2024 | 624 |
| Jun 2024 | 624 |
| Jul 2024 | 624 |
ADMA Biologics other data
29.23%
-48.49%
of ADMA is owned by hedge funds
99
-62
57.83M
-94.79M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 1500000 |
| Jun 2024 | 0 | 100000 |
| Aug 2024 | 0 | 847256 |
| Sep 2024 | 0 | 9000 |
| Nov 2024 | 0 | 63967 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | ELMS STEVE director | Common Stock | 9,000 | $10.8 | $97,200 | ||
Option | ELMS STEVE director | Stock Option (Right to Buy) | 9,000 | $10.8 | $97,200 | ||
Sale | TADE BRAD L. officer: CFO and Treasurer | Common Stock | 15,000 | $21.15 | $317,250 | ||
Sale | GROSSMAN ADAM S director, officer.. | Common Stock | 48,967 | $21.1 | $1,033,204 | ||
Option | GUIHEEN LAWRENCE P. director | Common Stock | 9,000 | $10.8 | $97,200 | ||
Sale | GUIHEEN LAWRENCE P. director | Common Stock | 9,000 | $18.47 | $166,185 | ||
Option | GUIHEEN LAWRENCE P. director | Common Stock | 9,000 | $10.8 | $97,200 | ||
Option | KESTENBERG-MESSINA KAITLIN M. officer: COO and SVP, Compliance | Common Stock | 5,000 | $4.72 | $23,600 | ||
Option | KESTENBERG-MESSINA KAITLIN M. officer: COO and SVP, Compliance | Common Stock | 6,650 | $5.94 | $39,501 | ||
Option | KESTENBERG-MESSINA KAITLIN M. officer: COO and SVP, Compliance | Common Stock | 4,375 | $2.59 | $11,331 |
| Patent |
|---|
Application Filling date: 2 Aug 2021 Issue date: 3 Feb 2022 |
Application Filling date: 9 Aug 2021 Issue date: 27 Jan 2022 |
Application Filling date: 9 Mar 2021 Issue date: 9 Sep 2021 |
Application Filling date: 15 Jun 2020 Issue date: 6 May 2021 |
Application Filling date: 30 Jul 2019 Issue date: 4 Feb 2021 |
Application Filling date: 15 Apr 2019 Issue date: 8 Aug 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Adam S. Grossman (1977) Co-Founder, Pres, Chief Executive Officer & Director | $1,130,000 |
Mr. Brian Lenz CPA, CPA (1972) Executive Vice President, Chief Financial Officer & GM of ADMA BioCenters | $802,870 |
| Dr. Jerrold B. Grossman Ph.D., D.P.S. (1948) Co-Founder & Vice Chairman | $70,900 |
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
3 'Buy-Rated' Biotech Stocks Under $10
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
ADMA Biologics: On A Roll Entering 2024
ADMA Biologics: FY22 Numbers Key Inflection Point
ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
I Would Avoid Verrica Pharmaceuticals Until CEO Change
ADMA Biologics: A Path To Profits Looks Clear
ADMA: Pertinent Updates
-
What's the price of ADMA Biologics stock today?
One share of ADMA Biologics stock can currently be purchased for approximately $17.48.
-
When is ADMA Biologics's next earnings date?
Unfortunately, ADMA Biologics's (ADMA) next earnings date is currently unknown.
-
Does ADMA Biologics pay dividends?
No, ADMA Biologics does not pay dividends.
-
How much money does ADMA Biologics make?
ADMA Biologics has a market capitalization of 4.12B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 67.59% to 258.21M US dollars.
-
What is ADMA Biologics's stock symbol?
ADMA Biologics, Inc. is traded on the NASDAQ under the ticker symbol "ADMA".
-
What is ADMA Biologics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ADMA Biologics?
Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ADMA Biologics's key executives?
ADMA Biologics's management team includes the following people:
- Mr. Adam S. Grossman Co-Founder, Pres, Chief Executive Officer & Director(age: 48, pay: $1,130,000)
- Mr. Brian Lenz CPA, CPA Executive Vice President, Chief Financial Officer & GM of ADMA BioCenters(age: 53, pay: $802,870)
- Dr. Jerrold B. Grossman Ph.D., D.P.S. Co-Founder & Vice Chairman(age: 77, pay: $70,900)
-
Is ADMA Biologics founder-led company?
Yes, ADMA Biologics is a company led by its founders Mr. Adam S. Grossman and Dr. Jerrold B. Grossman Ph.D., D.P.S..
-
How many employees does ADMA Biologics have?
As Jul 2024, ADMA Biologics employs 624 workers.
-
When ADMA Biologics went public?
ADMA Biologics, Inc. is publicly traded company for more then 11 years since IPO on 17 Oct 2013.
-
What is ADMA Biologics's official website?
The official website for ADMA Biologics is admabiologics.com.
-
Where are ADMA Biologics's headquarters?
ADMA Biologics is headquartered at 465 State Route 17, Ramsey, NJ.
-
How can i contact ADMA Biologics?
ADMA Biologics's mailing address is 465 State Route 17, Ramsey, NJ and company can be reached via phone at +20 14785552.
-
What is ADMA Biologics stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for ADMA Biologics in the last 12 months, the avarage price target is $18. The average price target represents a 2.97% change from the last price of $17.48.
ADMA Biologics company profile:
ADMA Biologics, Inc.
admabiologics.comExchange:
NASDAQ
Full time employees:
624
Industry:
Biotechnology
Sector:
Healthcare
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
465 State Route 17
Ramsey, NJ 07446
Ramsey, NJ 07446
CIK: 0001368514
ISIN: US0008991046
CUSIP: 000899104
